Investors can only ignore strong results for so long...

Sure, a narrative can drive stock prices in the short term. But over the long run, returns come from sales growth and higher profits.

Always remember, stock prices eventually follow earnings.

That's why, back in February, Doc wrote to you about the widespread sell-off in software stocks – and the opportunity for patient investors.

To recap, Software as a Service ("SaaS") stocks were hammered because the market was convinced AI would kill many of these companies. The narrative was simple... Why would a company pay millions of dollars each year to use enterprise software when AI could do the same tasks at a fraction of the cost?

Wall Street panicked. One trillion dollars in software market value disappeared within a week. And high-quality SaaS stocks took a beating... even though they were still making massive amounts of money.

Dubbed the "SaaSpocalypse," this market event was all anyone could talk about at the time. But Doc kept a level head and reminded Health & Wealth Bulletin readers to remain calm...

The market is currently in a "shoot first, ask questions later" phase. And a lot of quality software companies that are not going to be replaced by AI are being thrown out with the bathwater.

Yes, there are going to be software businesses that become obsolete because of AI. But many will be just fine since they'll use AI to keep their market share.

Now, the market is finally starting to wake up and realize that SaaS isn't going anywhere.

We can see this through the latest monthly return in the iShares Expanded Tech-Software Sector Fund (IGV)...

As you can see, software stocks just rose by the largest amount in a single month since 2001.

I'll repeat: Stock prices eventually follow earnings. And software companies have been posting strong earnings lately, helping to cool investor fears and put an end to the AI doomsday narrative.

The fatal flaw in the "AI will kill software" thesis was a misunderstanding of what a great software company actually provides. Wall Street was treating software like it's just raw code. It isn't.

For starters, software platforms often hold decades of proprietary customer data, historical transactions, regulatory compliance logs, and customized operational rules. Even if AI can generate similar software, it can't replace the trusted system of record that an organization has built its workflows around.

Plus, switching costs are high. It takes years and millions of dollars to train a workforce on a new system. Once a software product is woven into the daily habits of thousands of workers, it becomes a "toll booth" business. The cost of ripping it out outweighs almost any potential savings.

Most important, we're seeing many software companies use AI to make their products so good that big businesses wouldn't consider switching to a free tool.

Consider graphic-design company Adobe (ADBE). In its most recent quarter, total consumer usage of AI features grew by 45% from the previous quarter. And Adobe's annualized recurring revenue tied strictly to AI-first applications more than tripled year over year.

Adobe reports its next round of earnings next week. We suspect we'll see another quarter of high revenue growth, massive profit margins, and more signs that the business is using AI to become even stickier with its clients.

Doc previously noted that there's going to be a massive buying opportunity for many of the best software names. Of course, you never want to "catch a falling knife" and buy when a stock is still dropping.

However, software stocks are starting to gain momentum right now. Another few quarters of strong results and many of the best stocks are going to rocket off their basement valuations.

In Retirement Millionaire, we bought one of the best SaaS stocks in the market back in April. It was trading around the same valuation as it did during the 2008 financial crisis... despite the fact that it's already using AI to build more tools and cut down on costs.

We're up 13% on this position in just two months. But there are still plenty of gains to come, and the stock is still historically cheap.

Retirement Millionaire subscribers can see our recommendation here.

And if you aren't subscribed to Retirement Millionaire yet, click here to learn more.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Jeff Havenstein
June 3, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top